Singapore Markets closed
  • Straits Times Index

    -7.91 (-0.24%)
  • S&P 500

    +3.82 (+0.08%)
  • Dow

    -201.79 (-0.56%)
  • Nasdaq

    +86.95 (+0.59%)

    -895.08 (-2.09%)
  • CMC Crypto 200

    -24.76 (-2.41%)
  • FTSE 100

    -52.46 (-0.69%)
  • Gold

    -5.90 (-0.32%)
  • Crude Oil

    +1.46 (+1.74%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Nikkei

    -76.27 (-0.27%)
  • Hang Seng

    -105.25 (-0.43%)
  • FTSE Bursa Malaysia

    -12.41 (-0.80%)
  • Jakarta Composite Index

    -30.99 (-0.47%)
  • PSE Index

    +120.13 (+1.66%)

Bayer more stringent in glyphosate settlement talks due to downturn

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
FILE PHOTO: The logo of Bayer AG is seen in a showroom of the German drugmaker where the annual results news conference takes place in Leverkusen
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Ludwig Burger

FRANKFURT (Reuters) - Bayer <BAYGn.DE> said the economic downturn and the need to preserve cash means it is taking a tougher stance in talks to settle claims its glyphosate-based weedkillers cause cancer, even as its earnings rose.

The pandemic has significantly slowed the mediation process, the German drugs and pesticides company said in a statement on Monday.

"The company will consider a deal only if it is financially reasonable and puts in place a mechanism to resolve potential future claims efficiently," Chief Executive Werner Baumann said.

"This applies now more than ever," he added, citing a looming recession and considerable liquidity challenges as a result of the coronavirus pandemic.

The number of U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer reached 52,500, up from 48,600 in February, the company added.

Bayer denies claims that Roundup - or its active ingredient glyphosate - cause cancer, saying decades of independent studies have shown it to be safe for human use.

The company said first-quarter adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) rose 10.2% to 4.39 billion euros ($4.76 billion), surpassing average analyst expectations of 4.17 billion, according to Refinitiv data.

Bayer, which is due to hold its annual shareholder meeting in a virtual format on Tuesday, warned that it was unable to assess the impact of the pandemic on results this year.

The first-quarter beat was driven by a 14% gain in earnings at the agriculture division from higher sales of crop chemicals and corn seeds. Earnings were further underpinned by a 19% increase in revenue from stroke prevention drug Xarelto.

Bayer also pointed to the stockpiling of drugs as consumers purchased over-the-counter products and patients sought additional prescriptions as a safety net as the coronavirus spread.

Operating cash flow, however, fell to an outflow of 189 million euros, down from an inflow of 1 billion a year earlier, as it brought forward the settlement of agriculture payables and receivables were paid later.

"Despite this good performance, we have a question mark regarding cash-flows," said Bryan Garnier analyst Jean-Jacques Le Fur, also voicing concern about customers' creditworthiness in the farming sector.

Bayer's shares were up 3% at 61.36 euros by 0925 GMT, beating a 2% gain in the wider German market <.GDAXI>.

(Additional reporting by Patricia Weiss; editing by Thomas Seythal, Emma Thomasson, Kirsten Donovan)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting